NCT02163057View on ClinicalTrials.gov

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 13, 2014

Primary Completion Date

January 23, 2017

Study Completion Date

January 23, 2017

Conditions
Head and Neck Squamous Cell Cancer
Interventions
BIOLOGICAL

INO-3112

1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.

DEVICE

CELLECTRA™-5P

CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Inovio Pharmaceuticals

INDUSTRY

NCT02163057 - Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter